

[Chem. Pharm. Bull.]
32(12)4752—4757(1984)

Synthesis and Reactions of 3-(1,2,4-Triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxalines¹⁾

YOSHIHISA KURASAWA,* KUMI SUZUKI, SHOKO NAKAMURA,
KAYANO MORIYAMA, and ATSUSHI TAKADA

*School of Pharmaceutical Sciences, Kitasato University,
Shirokane, Minato-ku, Tokyo 108, Japan*

(Received March 27, 1984)

Various 3-(1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxalines (**4**—**7**, **10**, **11**) and related compounds (**8**, **9**) were synthesized using 3-hydrazinocarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (**2**) as a starting material.

Keywords—methyl isothiocyanate; allyl isothiocyanate; methyl iodide; nitrous acid; *m*-chloroperbenzoic acid; thiosemicarbazide; sulfur extrusion; polyphosphoric acid; benzoyl chloride

Many 1,3,4-oxadiazole derivatives possess fungicidal, herbicidal, and bactericidal activities,²⁾ and we have previously synthesized a novel type of 1,3,4-oxadiazoles, 3-(1,3,4-oxadiazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxalines (**1**), from 3-hydrazinocarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (**2**)³⁾ (Chart 1) in order to evaluate their activities. In addition, various 1,2,4-triazoles have been reported to possess bactericidal,⁴⁾ fungicidal,⁵⁾ antihistaminic,⁶⁾ and plant growth regulatory⁷⁾ activities, but there have been few reports on the synthesis and biological evaluation of 1,2,4-triazoles having a quinoxalinylmethylene moiety in the 3- or 5-position. This paper describes the synthesis and reactions of the above novel type of 1,2,4-triazoles as a part of our search for new agents having interesting biological activities.




Chart 1

The reactions of **2** with allyl and methyl isothiocyanates in dioxane gave the thiosemicarbazides (**3a** and **3b**, respectively), which were refluxed with potassium hydroxide in water to effect dehydration,⁸⁾ producing 3-(4-allyl-3,4-dihydro-3-thioxo-2*H*-1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (**4a**) and 3-(4-methyl-3,4-dihydro-3-thioxo-2*H*-1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (**4b**), respectively. Refluxing of **3a** and **3b** with 1,8-diazabicyclo[5.4.0]-7-undecene (DBU) in butanol also afforded **4a** and **4b**, respectively, in improved yields. Moreover, the reactions of **2** with allyl and methyl isothiocyanates in DBU and butanol directly provided **4a** and **4b**, respectively. The infrared (IR) spectra of **4a** and **4b** exhibited the C=S absorption bands near 1460 cm⁻¹, but showed no SH absorption band in the range of 2600—2550 cm⁻¹.⁹⁾ These data are con-

sistent with the structures of **4a** and **4b** shown in Chart 2.




Chart 2

The reaction of **4a** with methyl iodide resulted in S-methylation to give 3-(4-allyl-3-methylthio-4*H*-1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (**5**). Further refluxing of **5** with methyl iodide in *N,N*-dimethylformamide (DMF) afforded 3-(4-allyl-3,4-dihydro-2-methyl-3-thioxo-2*H*-1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (**6**), presumably *via* an *N*²'-methylated intermediate.¹⁰⁾ Moreover, the reaction of **5** with 2 equivalents of *m*-chloroperbenzoic acid (MCPBA) resulted in methylenic C-hydroxylation¹¹⁾ and N- or S-oxidation to furnish a yellow product. In the previous paper,¹⁾ the N-oxide structure was proposed for this product on the basis of the mass spectral (MS) data, which showed the [M-O (16)]⁺ and [M-OH (17)]⁺ fragment ion peaks (Table I) ordinarily observed in *ortho*-alkyl N-oxide compounds,¹²⁾ but lacked the [M-CO (28)]⁺ ion peak (characteristic of alkyl aryl and diaryl sulfoxides).¹³⁾ However, preferential S-oxidations have been reported in the reactions of di-2-pyridylmethyl sulfide¹⁴⁾ and 3-substituted 5-alkylthio-1,2,4-triazoles¹⁵⁾ with MCPBA and hydrogen peroxide-acetic acid, respectively. Therefore, the structure of the above product should be revised to 3-[1-(4-allyl-3-methylsulfinyl-4*H*-1,2,4-triazol-5-yl)-1-hydroxy]methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (**7**).

The reaction of **4b** with an excess of nitrous acid resulted in hydroxyimination¹⁶⁾ and sulfur extrusion^{15,17)} to produce 3-[1-hydroxyimino-1-(4-methyl-4*H*-1,2,4-triazol-3-yl)]-methylene-2-oxo-1,2-dihydroquinoxaline (**8**), presumably *via* intermediate A. Namely, it was assumed that the thiol group would be oxidized with nitrous acid to give intermediate A, whose C³'-sulfonic acid group was eliminated in the hot acidic medium.^{15,17)} Heating of **8** in polyphosphoric acid (PPA) resulted in dehydration¹⁶⁾ to afford 3-(4-methyl-4*H*-1,2,4-triazol-

TABLE I. Mass Spectral Data for 7

m/z	Ion species	Formula	Calcd	Found	Relat. intensity
345	$[M]^+$	$C_{15}H_{15}N_5O_3S$	345.090	345.091	100
329	$[M-O]^+$	$C_{15}H_{15}N_5O_2S$	329.092	329.090	23.6
328	$[M-OH]^+$	$C_{15}H_{14}N_5O_2S$	328.087	328.085	40.0
304	$[M-C_3H_5]^+$	$C_{12}H_{10}N_5O_3S$	304.050	304.049	49.4
289	$[M-C_3H_5-CH_3]^+$	$C_{11}H_7N_5O_3S$	289.027	289.029	70.2
288	$[M-O-C_3H_5]^+$ or $[M-C_3H_5-O]^+$	$C_{12}H_{10}N_5O_2S$	288.055	288.053	34.5

3-yl)isoxazolo[4,5-*b*]quinoxaline (**9**). The nuclear magnetic resonance (NMR) spectra of **8** and **9** showed the C^3 -H proton signals at δ 8.57 and 9.91 ppm, respectively, supporting the structural assignments of **8** and **9**.

The reactions of **3a** and **3b** in an excess of benzoyl chloride and dioxane also induced cyclization to the 1,2,4-triazole ring to produce 3-(4-allyl-3-benzoylthio-4*H*-1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (**10a**) and 3-(3-benzoylthio-4-methyl-4*H*-1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (**10b**), respectively. This type of cyclization with benzoyl chloride into a 1,2,4-triazole ring has already been reported by Marckwald *et al.*¹⁸⁾ The reactions of **2** with allyl and methyl isothiocyanates in an excess of benzoyl chloride and dioxane similarly afforded **10a** and **10b**, respectively. The C^3 -benzoylthio structures of **10a** and **10b** were elucidated by means of the following reactions. The reaction of **10b** with potassium hydroxide in ethanol caused debenzoylation to give **4b**, whose reaction with an excess of benzoyl chloride in dry pyridine and dioxane resulted in $N^{2'}$ -benzoylation to furnish 3-(2-benzoyl-3,4-dihydro-4-methyl-3-thioxo-2*H*-1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (**11**). The $N^{2'}$ -benzoylation under such conditions has already been reported by Tsitsika *et al.*¹⁹⁾ The above results are shown in Chart 3. The NMR spectral data provided additional evidence for the structures of the benzoylated




Chart 3

compounds **10a**, **10b**, and **11**. The vinyl proton signals of the dihydrotriazole compounds [N^2 -H (**4a**) and $N^{2'}$ -NMe (**6**)] were observed at δ 5.88 and 5.87 ppm, respectively, but the vinyl proton signal of the aromatized triazole compound (**5**) was observed at a lower magnetic field (δ 5.97 ppm) than those of **4a** and **6**. This tendency was also found in the 3-(1,3,4-oxadiazol-2-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxalines (**12a** and **12b** Chart 4);²⁰⁾ the vinyl proton signal of the aromatized oxadiazole compound **12a** was observed at a lower magnetic field (δ 6.00 ppm) than that of the dihydrooxadiazole compound **12b** (δ 5.85 ppm). On the other hand, no difference was found in the chemical shifts of the vinyl proton signals between the N^2 -H (**4b**) and $N^{2'}$ -benzoyl (**11**) compounds of the dihydrotriazole form (both δ 5.93 ppm). Furthermore, the NMR spectra of **10a** and **10b** exhibited the vinyl proton signals at a lower magnetic field (both δ 6.42 ppm) than those of **5** and **12a**, supporting the conclusion

that **10a** and **10b** possessed the aromatized 1,2,4-triazole ring with the benzoylthio group at the 3'-position.




Chart 4

NMR Spectral Features of the Products

The NMR spectra of 3-alkoxycarbonylmethylene-2-oxo-1,2,3,4-tetrahydroquinoxalines in dimethylsulfoxide- d_6 (DMSO- d_6) have been reported to reveal the presence of two tautomers, I and II,²¹⁾ as shown in Chart 5. Compounds **3**—**6**, **10**, and **11** also displayed this tautomerism in DMSO- d_6 , and hence the signals due to these two tautomers are observed. The integral ratios of the vinyl (I) and methylene (II) proton signals in the NMR spectra of **3b**, **4b**, **10a**, **10b**, and **11** at 30 °C were 1:1, 1:0.7, 4.5:1, 4:1, and 1:1.5, respectively, while the integral ratios of the other compounds could not be calculated, since either the vinyl or the methylene proton signal overlapped with other signals.




Chart 5

Experimental

All melting points are uncorrected. IR spectra were recorded from KBr discs on a JASCO IRA-1 spectrophotometer. NMR spectra were measured in DMSO- d_6 (except for **9**) with an EM-390 spectrometer at 90 MHz using tetramethylsilane as an internal standard. Chemical shifts are given in the δ scale, relative to the internal standard. MS were determined with a JMS-O1S spectrometer (Japan Electron Optics Laboratory Co., Ltd.).

Thiosemicarbazides 3a and 3b—A suspension of **2** (10 g, 45.9 mmol) and the appropriate isothiocyanate (equimolar amount) in dioxane (200 ml) was refluxed for 1 h in an oil bath to precipitate a colorless powder, **3a** or **3b**, which was collected by suction filtration.

Compound 3a—Yield, 13.73 g (94.4%). Trituration with hot EtOH gave an analytically pure sample, mp 230—232 °C. MS m/z : 317 (M^+). IR ν_{\max} : 3300, 1690, 1640 cm^{-1} . NMR: 12.43 (s), 11.43 (s), 10.13 (s), 9.63 (s), 9.40 (s), and 9.15 (s) (4H, NH),²¹⁾ 8.10 (t, $J=4.5$ Hz, 1H, CSNHCH₂CH=CH₂), 8.00—6.70 (m, 4H, aromatic), 5.83 (m, 1H, —CH₂—CH=CH₂), 5.68 (s, C³=CH—),²¹⁾ 5.30—4.87 (m, 2H, —CH₂—CH=CH₂), 4.10 (m, 2H, —CH₂—CH=CH₂), 3.72 (s, C³—CH₂—),²¹⁾ Anal. Calcd for C₁₄H₁₅N₅O₂S: C, 52.98; H, 4.76; N, 22.07. Found: C, 53.09; H, 4.76; N, 21.85.

Compound 3b—Yield, 12.91 g (96.7%). Trituration with hot EtOH afforded an analytically pure sample, mp 256—258 °C. MS m/z : 291 (M^+). IR ν_{\max} : 3300, 3160, 3010, 1670, 1630 cm^{-1} . NMR: 11.50 (s), 10.00 (s), 9.33 (s), and 9.10 (s) (4H, NH),²¹⁾ 7.90 (q, $J=4.5$ Hz, 1H, CSNHMe), 7.83—6.67 (m, 4H, aromatic), 5.68 (s, C³=CH—),²¹⁾ 3.73 (C³—CH₂—),²¹⁾ 2.94 (d, $J=4.5$ Hz) and 2.88 (d, $J=4.5$ Hz) (3H, CSNHMe).²¹⁾ The Me proton signals split into two on addition of D₂O. Anal. Calcd for C₁₂H₁₃N₅O₂S: C, 49.47; H, 4.50; N, 24.04. Found: C, 49.27; H, 4.44; N, 23.76.

3-(4-Allyl-3,4-dihydro-3-thioxo-2H-1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (4a) and **3-(4-Methyl-3,4-dihydro-3-thioxo-2H-1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (4b)**—From the Thiosemicarbazides **3a** and **3b** (Method A): A suspension of the appropriate thiosemicarbazide (1 g) and KOH (1.5 eq) in H₂O (30 ml) was refluxed in an oil bath for 1 h to precipitate the product **4a** or **4b** as a yellow powder, which

was collected by suction filtration. Trituration with hot EtOH–H₂O gave an analytically pure sample.

From the Thiosemicarbazide **3a** and **3b** (Method B): A suspension of the appropriate thiosemicarbazide (10 g) and DBU (2 ml) in BuOH (400 ml) was refluxed in an oil bath for 2 h to precipitate the product **4a** or **4b** as a yellow powder, which was collected by filtration. Trituration with hot EtOH afforded an analytically pure sample.

One-Pot Synthesis from the Hydrazide **2** (Method C): A suspension of the hydrazide **2** (5 g), the appropriate isothiocyanate (equimolar amount), and DBU (1 ml) in BuOH (200 ml) was refluxed in an oil bath for 5 h to precipitate the product **4a** or **4b** as a yellow powder, which was collected by suction filtration. Trituration with hot EtOH gave an analytically pure sample.

Compound 4a—Yield, 0.76 g (81%) in method A, 8.02 g (85.5%) in method B, 4.74 g (69.1%) in method C, mp 334–336 °C. MS *m/z*: 299 (*M*⁺). IR *v*_{max}: 3120, 3060, 3010, 1680, 1640, 1610, 1260 cm⁻¹. NMR: 13.81 (s), 13.57 (s), 12.40 (s), and 11.46 (s) (2H, N¹– and N⁴–H),²¹⁾ 10.03 (s, 1H, N²–H), 7.77–6.67 (m, 4H, aromatic), 5.88 (s, C³ = CH–),²¹⁾ 5.86 (m, 1H, –CH₂–CH = CH₂), 5.30–4.83 (m, 2H, –CH₂–CH = CH₂), 4.68 (dd, *J* = 4.5 Hz, 2H, –CH₂–CH = CH₂), 4.18 (s, C³–CH₂–).²¹⁾ Anal. Calcd for C₁₄H₁₃N₅OS: C, 56.17; H, 4.38; N, 23.40. Found: C, 56.05; H, 4.39; N, 23.22.

Compound 4b—Yield, 0.28 g (29.9%) in method A, 8.74 g (93.2%) in method B, 5.1 g (81.5%) in method C, mp above 340 °C. MS *m/z*: 273 (*M*⁺). IR *v*_{max}: 3120, 3060, 3010, 1680, 1640, 1610, 1270, 1260 cm⁻¹. NMR: 13.78 (s), 13.47 (s), 12.40 (s), and 11.43 (s) (2H, N¹– and N⁴–H),²¹⁾ 10.00 (s, 1H, N²–H), 7.77–6.77 (m, 4H, aromatic), 5.93 (s, C³ = CH–),²¹⁾ 4.27 (s, C³–CH₂–),²¹⁾ 3.53 (s) and 3.50 (s) (3H, N⁴–Me).²¹⁾ Anal. Calcd for C₁₂H₁₁N₅OS: C, 52.73; H, 4.06; N, 25.63. Found: C, 52.90; H, 4.10; N, 25.75.

3-(4-Allyl-3-methylthio-4H-1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (5)—A solution of **4a** (4.22 g, 16.7 mmol), MeI (2.61 g, 18.4 mmol), and DBU (2.80 g, 18.4 mmol) in EtOH (250 ml) was refluxed on a boiling water bath for 3 h. Removal of the solvent by evaporation gave yellow crystals **5** (3.37 g, 76.2%). Recrystallization from EtOH afforded yellow needles, mp 213–214 °C. MS *m/z*: 313 (*M*⁺). IR *v*_{max}: 1675, 1635, 1615 cm⁻¹. NMR: 11.33 (s, 1H, N¹–H), 11.13 (s, 1H, N⁴–H), 7.23–6.73 (m, 4H, aromatic), 5.97 (s, C³ = CH–),²¹⁾ 5.92 (m, 1H, –CH₂–CH = CH₂), 5.30–4.53 (m, 4H, –CH₂–CH = CH₂), 4.23 (s, C³–CH₂–),²¹⁾ 2.63 (s) and 2.58 (s) (3H, SMe).²¹⁾ Anal. Calcd for C₁₅H₁₅N₅OS: C, 57.49; H, 4.82; N, 22.35. Found: C, 57.49; H, 4.74; N, 22.18.

3-(4-Allyl-3,4-dihydro-2-methyl-3-thioxo-2H-1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (6)—A solution of **5** (2 g, 6.39 mmol) and MeI (1.36 g, 9.60 mmol) in DMF (50 ml) was refluxed in an oil bath for 1 h. Removal of the solvent by evaporation provided yellow needles **6** (0.91 g, 45.5%). Trituration with hot EtOH gave analytically pure yellow needles, mp 285–287 °C. MS *m/z*: 313 (*M*⁺). IR *v*_{max}: 1680, 1640, 1610, 1270, 1255 cm⁻¹. NMR: 12.37 (s), 11.40 (s), and 10.08 (s), (2H, N¹– and N⁴–H),²¹⁾ 7.60–6.70 (m, 4H, aromatic), 5.90 (m, 1H, –CH₂–CH = CH₂), 5.87 (s, C³ = CH–),²¹⁾ 5.27–4.57 (m, 4H, –CH₂–CH = CH₂), 4.18 (s, C³–CH₂–),²¹⁾ 3.79 (s) and 3.76 (s) (3H, N²–Me).²¹⁾ Anal. Calcd for C₁₅H₁₅N₅OS: C, 57.49; H, 4.82; N, 22.35. Found: C, 57.29; H, 4.62; N, 22.64.

3-[1-(4-Allyl-3-methylsulfinyl-4H-1,2,4-triazol-5-yl)-1-hydroxy]methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (7)—A solution of **5** (5 g, 16.0 mmol) and MCPBA (6.90 g, 2 eq) in EtOH (200 ml) was refluxed on a boiling water bath for 5 h. The solution was filtered while hot, and yellow needles precipitated. They were collected by filtration (0.94 g, 18%). Recrystallization from EtOH provided analytically pure yellow needles, mp 229–231 °C. MS *m/z*: 345 (*M*⁺). IR *v*_{max}: 3220, 1650, 1610 cm⁻¹. NMR: 12.03 (s, 1H, N¹–H), 11.22 (s, 1H, N⁴–H), 9.85 (s, 1H, OH), 7.30–6.53 (m, 4H, aromatic), 6.00 (m, 1H, –CH₂–CH = CH₂), 5.40–4.92 (m, 4H, –CH₂–CH = CH₂), 3.20 (s, 3H, SMe). Anal. Calcd for C₁₅H₁₅N₅O₃S: C, 52.16; H, 4.38; N, 20.28. Found: C, 52.32; H, 4.41; N, 20.28.

3-[1-Hydroxyimino-1-(4-methyl-4H-1,2,4-triazol-3-yl)]methylene-2-oxo-1,2-dihydroquinoxaline (8)—A solution of NaNO₂ (6.32 g, 91.6 mmol) in H₂O (60 ml) was added dropwise to a suspension of **4b** (5 g, 18.3 mmol) in H₂O (40 ml) and AcOH (200 ml) with stirring in an ice-water bath. The suspension was heated on a boiling water bath for 2 h. Removal of the solvent by evaporation provided colorless needles (3.89 g, 78.6%). Trituration with hot AcOH afforded analytically pure colorless needles, mp 295–297 °C. MS *m/z*: 270 (*M*⁺). IR *v*_{max}: 3140, 1690, 1610 cm⁻¹. NMR: 12.53 (s) and 12.18 (s) (2H, N¹–H and OH), 8.57 (s, 1H, C³–H), 7.90–7.20 (m, 4H, aromatic), 3.87 (s, 3H, Me). Anal. Calcd for C₁₂H₁₀N₆O₂: C, 53.33; H, 3.73; N, 31.10. Found: C, 53.13; H, 3.66; N, 31.00.

3-(4-Methyl-4H-1,2,4-triazol-3-yl)isoxazolo[4,5-*b*]quinoxaline (9)—A solution of **8** (5 g) in polyphosphoric acid [H₃PO₄ (20 ml) and P₂O₅ (10 g)] was heated in an oil bath at 100–110 °C (bath temperature) with stirring for 4 h. The solution was cooled in an ice-water bath and then poured onto crushed ice. Yellow crystals precipitated, and were collected by suction filtration (1.86 g, 39.8%). Recrystallization from EtOH gave yellow needles, mp 303–305 °C. MS *m/z*: 252 (*M*⁺). IR *v*_{max}: 1590, 1555, 1515, 1500 cm⁻¹. NMR (CF₃COOH): 9.91 (s, 1H, C³–H), 8.70–8.00 (m, 4H, aromatic), 4.62 (s, 3H, Me). Anal. Calcd for C₁₂H₈N₆O: C, 57.14; H, 3.20; N, 33.32. Found: C, 57.33; H, 3.07; N, 33.34.

3-(4-Allyl-3-benzoylthio-4H-1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (10a) and 3-(3-Benzoylthio-4-methyl-4H-1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (10b)—From the Thiosemicarbazides **3a** and **3b** (Method A): A suspension of the appropriate thiosemicarbazide (5 g) in benzoyl chloride (20 ml) and dioxane (100 ml) was refluxed in an oil bath for 4 h to give a clear solution. Removal of the solvent and excess benzoyl chloride by evaporation left an oily mixture, which was triturated with EtOH–H₂O (2:1, v/v) (300 ml) on a boiling water bath to precipitate yellow crystals **10a** or **10b**. The yellow crystals **10a** or **10b** were

immediately collected by suction filtration. Further trituration with hot EtOH afforded an analytically pure yellow powder, **10a** or **10b**.

One-Pot Synthesis from the Hydrazide 2 (Method B): A suspension of **2** (10 g, 45.9 mmol) and the appropriate isothiocyanate (equimolar amount) in dioxane (200 ml) was refluxed in an oil bath for 1 h to precipitate colorless crystals, **3a** and **3b**. Benzoyl chloride (40 ml) was added to this suspension, and refluxing was continued for an additional 8 h or 14 h in the case of **3a** or **3b**, respectively. Removal of the solvent and excess benzoyl chloride gave an oily mixture, which was triturated with EtOH-H₂O (2:1, v/v) (600 ml) on a boiling water bath to precipitate the product, **10a** or **10b**. The subsequent procedure is similar to that described in method A.

Compound 10a—Yield, 2.04 g (32.1%) in method A, 5.72 g (30.9%) in method B, mp 213–215 °C. MS *m/z*: 403 (*M*⁺). IR *v*_{max}: 1680, 1645, 1625, 1610 cm⁻¹. NMR: 12.43 (s), 11.36 (s), and 11.22 (s) (2H, N¹- and N⁴-H),²¹⁾ 8.00–6.77 (m, 9H, aromatic), 6.42 (s, C³=CH-),²¹⁾ 5.93 (m, 1H, -CH₂-CH=CH₂), 5.18–4.87 (m, 2H, -CH₂-CH=CH₂), 4.70 (m, -CH₂-CH=CH₂), 4.56 (s, C³-CH₂-).²¹⁾ Anal. Calcd for C₂₁H₁₇N₅O₂S: C, 62.52; H, 4.25; N, 17.36. Found: C, 62.70; H, 4.25; N, 17.10.

Compound 10b—Yield, 2.10 g (32.1%) in method A, 6.93 g (40.1%) in method B, mp 301–303 °C. MS *m/z*: 377 (*M*⁺). IR *v*_{max}: 1680, 1655, 1635, 1610 cm⁻¹. NMR: 12.43 (s), 11.40 (s), and 11.32 (s) (2H, N¹- and N⁴-H),²¹⁾ 8.00–6.80 (m, 9H, aromatic), 6.42 (s, C³=CH-),²¹⁾ 4.56 (s, C³-CH₂-),²¹⁾ 3.60 (s) and 3.56 (s) (3H, NMe).²¹⁾ Anal. Calcd for C₁₉H₁₅N₅O₂S: C, 60.47; H, 4.01; N, 18.56. Found: C, 60.31; H, 3.90; N, 18.41.

3-(2-Benzoyl-3,4-dihydro-4-methyl-3-thioxo-2H-1,2,4-triazol-5-yl)methylene-2-oxo-1,2,3,4-tetrahydroquinoxaline (11)—A solution of **4b** (2 g, 7.3 mmol) and benzoyl chloride (1.23 g, 8.76 mmol) in pyridine (10 ml) and dioxane (40 ml) was refluxed in an oil bath for 6 h to yield a clear solution. The solution was filtered while hot. An analytically pure sample precipitated as yellow needles (mp 271–273 °C), which were collected by filtration (1.2 g, 43.5%). MS *m/z*: 377 (*M*⁺). IR *v*_{max}: 1720, 1680, 1640, 1620, 1600 cm⁻¹. NMR: 12.43 (s), 11.55 (s), and 9.93 (s) (N¹- and N⁴-H),²¹⁾ 8.00–6.70 (m, 9H, aromatic), 5.93 (s, C³=CH-),²¹⁾ 4.35 (s, C³-CH₂-),²¹⁾ 3.53 (s) and 3.49 (s) (3H, NMe).²¹⁾ Anal. Calcd for C₁₉H₁₅N₅O₂S: C, 60.47; H, 4.01; N, 18.56. Found: C, 60.24; H, 3.97; N, 18.63.

References and Notes

- 1) A part of this work was reported by Y. Kurasawa, K. Suzuki, S. Nakamura, K. Moriyama, and A. Takada in *Heterocycles*, **22**, 695 (1984).
- 2) Y. Kurasawa, Y. Moritaki, T. Ebukuro, and A. Takada, *Chem. Pharm. Bull.*, **31**, 3897 (1983).
- 3) Y. Kurasawa, Y. Moritaki, and A. Takada, *Synthesis*, **1983**, 238.
- 4) G. Mazzone, F. Bonina, and G. Blandino, *Farmaco. Ed. Sci. (Ital.)*, **36**, 1004 (1981) [*Chem. Abstr.*, **96**, 122698m (1982)].
- 5) *Chem. Abstr.*, **96**, 104256m, 104257n, 104258p (1982).
- 6) *Chem. Abstr.*, **96**, 20114a (1982).
- 7) *Chem. Abstr.*, **96**, 199710s, 104256m (1982).
- 8) J. H. Winkel and C. J. Paget, *J. Org. Chem.*, **39**, 3506 (1974).
- 9) A. J. Blackman and J. B. Polya, *J. Chem. Soc. (C)*, **1970**, 2403.
- 10) P. Molina and M. Alajarin, *Synthesis*, **1983**, 414.
- 11) Y. Kurasawa, Y. Moritaki, and A. Takada, *Heterocycles*, **19**, 1619 (1982).
- 12) R. Grigg and B. G. Odell, *J. Chem. Soc. (B)*, **1966**, 218.
- 13) I. D. Entwistle, R. A. W. Johnstone, and B. J. Millard, *J. Chem. Soc. (C)*, **1967**, 302; J. H. Bowie, D. H. Williams, S.-O. Lawesson, J. Ø. Madsen, C. Nolde, and G. Schroll, *Tetrahedron*, **22**, 3515 (1966).
- 14) H. J. J.-B. Martel and M. Rasmussen, *Tetrahedron Lett.*, **1971**, 3843.
- 15) C. Temple, Jr., "The Chemistry of Heterocyclic Compounds, Triazoles 1, 2, 4," Vol. 37, ed. by J. A. Montgomery, John Wiley and Sons, New York, Chichester, Brisbane, Toronto, 1981, p. 301, 315, and references cited therein.
- 16) D. D. Chapman, *J. Org. Chem.*, **37**, 2498 (1972).
- 17) M. Fieser and L. Fieser, "Reagents for Organic Synthesis," Vol. 1, John Wiley and Sons, New York, London, Sydney, 1967, p. 463.
- 18) L. L. Bambas, "The Chemistry of Heterocyclic Compounds," Vol. 4, ed. by A. Weissberger, Interscience Publishers, New York, London, 1952, p. 105, and references cited therein.
- 19) C. Temple, Jr., "The Chemistry of Heterocyclic Compounds, Triazoles 1, 2, 4," Vol. 37, ed. by J. A. Montgomery, John Wiley and Sons, New York, Chichester, Brisbane, Toronto, 1981, p. 489, and references cited therein.
- 20) Y. Kurasawa, S. Nakamura, K. Moriyama, K. Suzuki, and A. Takada, *Heterocycles*, **22**, 1189 (1984).
- 21) R. Mondelli and L. Merlini, *Tetrahedron*, **22**, 3253 (1966).